Assertio Therapeutics

Paratek Pharmaceuticals, based in King Of Prussia, PA, is a biopharmaceutical company dedicated to addressing the critical global public health issue of antimicrobial resistance (AMR). Their FDA-approved tetracycline class antibiotic, Nuzyra, is designed to treat adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. With a disciplined team of innovative professionals, Paratek is committed to developing and commercializing new treatment options for complex medical issues, including combating the ongoing pandemic of AMR. Led by CEO Evan Loh, M.D., the company strives to provide life-saving solutions to defeat superbugs and improve public health and national security. Generated from the website

CSL Behring is one of the leading providers of plasma protein biotherapeutic products in the world. It is a pharmaceutical company engaged in the research and development of life-saving biotherapies for the treatment of coagulation disorders, such as hemophilia and von Willebrand diseases. The company additionally manufactures a variety of medicines and drugs for the treatment of immune deficiencies, genetic emphysema, sepsis, severe burns, wounds and heomolytic diseases. It also provides medicines for transplantation, coagulation, immunology and critical care applications. The company supplies products under the Cytogam, Helixate, Humate-P, Monoclate-P, Mononine, Stimate, AlbuRx, Albuminar and Vivaglobin brands. It offers sales, marketing, distribution, online ordering and customer support services. The company maintains CSL Plasma, which is a plasma collection network that operates throughout the United States and Germany. CSL Behring is a part of CSL Limited, which is an Australia-based company that supplies sera and vaccines.

Trevena, Inc is an innovative biopharmaceutical company based in Chesterbrook, PA, dedicated to developing groundbreaking medicines for patients with central nervous system (CNS) disorders. Their pipeline includes one FDA-approved product, OLINVYK oliceridine injection, and three differentiated investigational drug candidates, targeting various therapeutic areas such as acute pain, diabetic neuropathic pain, epilepsy, acute migraine, and opioid use disorder. With a focus on targeted and innovative CNS therapies, Trevena's pipeline is built on Nobel Prize-winning research and aims to address the critical needs of patients. Their commitment to innovation and patient care drives their mission to deliver effective treatments for CNS disorders.Generated from the website